Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

WRAPUP 2-AstraZeneca resumes U.S. COVID-19 vaccine trial, optimism seen for J&J

Fri, 23rd Oct 2020 20:54

(Adds background details)

Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.

AstraZeneca's U.S. trial was paused on Sept. 6 after a
report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.

U.S. Health and Human Services Deputy Chief of Staff Paul
Mango also told reporters he was optimistic a U.S. trial by
Johnson & Johnson would resume.

J&J paused its large, late-stage trial last week after a
study participant became ill and the company said an independent
safety panel was investigating.

AstraZeneca trials in the United Kingdom, Brazil and South
Africa resumed last month even as the U.S. Food and Drug
Administration continued its investigation into the case.

Reuters earlier this week reported that the FDA had
completed its review and that the AstraZeneca U.S. trial was set
to resume as early as this week, citing four sources familiar
with the situation.

AstraZeneca's vaccine is being developed along with
researchers at Oxford University.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva, Rosalba O'Brien and Grant McCool)

Related Shares

More News

IN BRIEF: DeepMatter partners with universities on automated precision

IN BRIEF: DeepMatter partners with universities on automated precision

17 Jun 21 19:14

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

Redx Pharma gets milestone sum from AstraZeneca for therapy progress

17 Jun 21 14:07

Thursday broker round-up

(Sharecast News) - Pets At Home: Liberum upgrades to buy with a target price of 510p.

17 Jun 21 13:49

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

17 Jun 21 09:48

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.